Detection of coxsackie-adenovirus receptor (CAR) immunoreactivity in ovarian tumors of epithelial derivation

Applied Immunohistochemistry

Volumn 7, Issue 4, 1999, Pages 266-270

  Khuu, Hanh ^a   Conner, Michael ^a   Vanderkwaak, Timothy ^a   Shultz, Jana ^a   Gomez Navarro, Jesus ^a   Alvarez, Ronald D ^a   Curiel, David T ^a   Siegal, Gene P ^a,b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Coxsackie adenovirus receptor; Immunohistochemistry; Ovary

Indexed keywords

VIRUS RECEPTOR;

ADENOVIRUS; ARTICLE; COXSACKIE VIRUS; ENDOMETRIUM; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; OVARY TUMOR; PRIORITY JOURNAL; VIRUS DETECTION;

EID: 0032787324     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-199912000-00004     Document Type: Article

References (36)

1. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
2. Dranoft G. Cancer gene therapy: connecting basic research with clinical inquiry. J Clin Oncol 1998;16:2548-56.
3. Blaese RM. Gene therapy for cancer. Sci Am 1997;276:111-5.
4. Anderson WF. Human gene therapy. Nature 1998;393(suppl):25-30.
5. Culver KW. Gene therapy for malignant neoplasms of the CNS. Bone Marrow Transplant 1996;18(suppl):S6-9.
6. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993;4:39-69.
7. Albelda SM. Gene therapy for lung cancer and mesothelioma. Chest 1997;111(6 suppl):144S-9S.
8. Sterman DH, Kaiser LR, Albelda SM. Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 1998;12: 553-68.
9. Barnes MN, Deshane JS, Rosenfeld M, Siegal GP, Curiel DT, Alvarez RD. Gene therapy and ovarian cancer: a review. Obstet Gynecol 1997;89:145-55.
10. Robertson MW, Barnes MN, Rancourt C, et al. Gene therapy for ovarian carcinoma. Semin Oncol 1998;25:397-406.
11. Tait DL, Obermiller PS, Jensen A, Holt JT. Ovarian cancer gene therapy. Hematol Oncol Clin North Am 1998;12:539-51.
12. Gomez-Navarro J, Siegal GP, Alvarez RD, Curiel DT. Gene therapy: ovarian carcinoma as the paradigm. Am J Clin Pathol 1998;109:444-67.
13. Markman, M. Intraperitoneal therapy of ovarian cancer. Semin Oncol 1998;25:356-60.
14. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998;25:340-8.
15. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. Adv Pharmacol 1997;40:137-206.
16. Wivel NA, Wilson JM. Methods of gene delivery. Hematol Oncol 1998;12:483-501.
17. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-3.
18. Hsu KH, Lonberg-Holm K, Alstein B, Crowell RL. A monoclonal antibody specific for the cellular receptor for the group B coxsackievirus. J Virol 1988;62:1647-52.
19. Mapoles JE, Krah DL, Crowell RL. Purification of a HeLa cell receptor protein for group B coxsackieviruses. J Virol 1985;55: 560-6.
20. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 1997;94:3352-6.
21. Wang X, Bergelson JM. Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection. J Virol 1999;73:2559-62.
22. Hemmi S, Geertsen R, Mezzacasa A, et al. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998;9:2363-73.
23. Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999;59:325-30.
24. Pileri SA, Roncador G, Ceccarelli C, et al. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol 1997;183:116-23.
25. Shi S, Cote RJ, Yang C, et al. Development of an optimal protocol for antigen retrieval: a "test battery" approach exemplified with reference to the staining of retinoblastoma protein (pRB) in formalin-fixed paraffin sections. J Pathol 1996;179:347-52.
26. Werner M, von Wasielewski R, Komminoth P. Antigen retrieval, signal amplification and intensification in immunohistochemistry. Histochem Cell Biol 1996;105:253-60.
27. Shi S, Cote RJ, Taylor CR. Antigen retrieval past, present, and future. J Histochem Cytochem 1997;45:327-43.
28. Crowell RL, Field AK, Schleif WA, et al. Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade. J Virol 1986;57: 438-45.
29. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
30. Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997;349:113-7.
31. Young RC, Pecorelli S. Management of early ovarian cancer. Semin Oncol 1998;25:335-9.
32. Schilder RJ, Shea TC. Multiple cycles of high-dose chemotherapy for ovarian cancer. Semin Oncol 1998;25:349-55.
33. Lanciano R, Reddy S, Corn B, Randall M. Update on the role of radiotherapy in ovarian cancer. Semin Oncol 1998;25:361-71.
34. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998;25:326-34.
35. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083-92.
36. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackie and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13.